Insider Selling: Cellebrite DI (NASDAQ:CLBT) Insider Sells 3,049 Shares of Stock

Cellebrite DI logo with Technology background
Image from MarketBeat Media, LLC.

Key Points

  • Cellebrite insider Holly Windham sold 3,049 shares at an average of $10.65, for about $32,472. The sale reduced Windham’s stake by 3.2%, leaving 92,279 shares.
  • Analysts have a “Moderate Buy” consensus and an average price target of $14.75; four rate the stock Buy and one rates it Sell.
  • Institutional investors own 45.88% of Cellebrite’s shares, and several large funds—including Wellington Management and Light Street Capital—recently increased their holdings.
  • MarketBeat previews the top five stocks to own by December 1st.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) insider Holly Windham sold 3,049 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $10.65, for a total transaction of $32,471.85. Following the completion of the transaction, the insider owned 92,279 shares in the company, valued at approximately $982,771.35. The trade was a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT opened at $11.16 on Thursday. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 46.50, a PEG ratio of 1.35 and a beta of 1.06. The firm's 50-day simple moving average is $11.57 and its 200 day simple moving average is $13.15. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.39.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CLBT. Lake Street Capital lowered their price objective on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. DA Davidson reissued a "buy" rating and issued a $15.00 price objective on shares of Cellebrite DI in a research report on Tuesday, September 15th. Needham & Company LLC upped their target price on Cellebrite DI from $12.50 to $14.00 and gave the stock a "buy" rating in a report on Thursday, November 12th. JPMorgan Chase & Co. cut their price target on shares of Cellebrite DI from $16.00 to $15.00 and set an "overweight" rating on the stock in a research note on Friday, November 13th. Finally, Weiss Ratings upgraded Cellebrite DI from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $14.75.

Check Out Our Latest Stock Report on CLBT

Hedge Funds Weigh In On Cellebrite DI

A number of large investors have recently modified their holdings of the business. Light Street Capital Management LLC raised its position in shares of Cellebrite DI by 104.8% in the second quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company's stock valued at $19,166,000 after buying an additional 671,830 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Cellebrite DI during the first quarter worth about $2,134,000. Nine Ten Capital Management LLC boosted its position in Cellebrite DI by 19.8% during the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company's stock worth $60,251,000 after acquiring an additional 682,933 shares during the period. Wellington Management Group LLP grew its holdings in Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company's stock worth $44,529,000 after acquiring an additional 1,475,579 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Cellebrite DI by 14.7% during the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company's stock valued at $39,420,000 after acquiring an additional 365,700 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company's offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

Featured Articles

Insider Buying and Selling by Quarter for Cellebrite DI (NASDAQ:CLBT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cellebrite DI Right Now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines